Boehringer to sell vaccine lines to ElancoOctober 5, 2016Elanco Animal Health plans to acquire more than 40 vaccines from Boehringer Ingelheim Vetmedica Inc. in a transaction valued at $885 million, the companies announced today.
SPONSORED CONTENTStart Treating Canine MMVD Patients at Stage B2Learn about early treatment with pimobendan for canine Stage B2 preclinical MMVD patients. + Learn More
BIVI's Bordetella vaccine tops 17 million dosesMay 12, 201617 million doses and counting. Boehringer Ingelheim Vetmedica Inc. reported the milestone sales figure Tuesday for Bronchi-Shield Oral, a four-year-old canine Bordetella vaccine.